#Tyrosine kinase inhibitors are #targeted_therapies for #cancer.
Tyrosine-kinase inhibitors include neratinib (Nerlynx), which is FDA-approved for the treatment of HER2-positive early breast cancer, and lapatinib (Tykerb), which is FDA-approved for the treatment of HER2-positive metastatic breast cancer.
Join with us in #Rome, Italy at #October15_16,2018 With our grand #World Congress on Breast Cancer
Save your #Dates and be a #Speaker for the conference.
contact us for queries regarding conference : breastcancer@pulsusevents.org | breastcancer@pulsusmeet.org
submit an #Abstract on-https://bit.ly/2IaExiN
Registration-https://bit.ly/2s5WVDn
Visit the site for more details-https://bit.ly/2s8xD6O
download the brochure-https://bit.ly/2rzvssM
No comments:
Post a Comment